Velum, Inc.
Publicly observedCambridge, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Cambridge | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Velum, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | Y5DJXLQZL6F8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Peptide YY triagonist weight loss drugs
USD 315,342.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2022Publicly observed
NIH SBIR/STTR award: A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome
USD 959,031.00 · National Institute of Diabetes and Digestive and Kidney Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.